discusses first the background in terms of development of
these agents and safety discussions therein, and second their relative
stability based both on in vitro studies and clinical observations
before and including the advent of nephrogenic systemic fibrosis. This
sets the stage for the subsequent focus of the review, the current
knowledge regarding accumulation of gadolinium in the brain and
specifically the dentate nucleus after intravenous administration of the
GBCAs and differentiation among agents on this basis.